Invesco Ltd. Gracell Biotechnologies Inc. Transaction History

Invesco Ltd.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$2.43 - $10.04 $5,499 - $22,720	-2,263 Reduced 3.47%	62,863 $631,000
Q3 2023 Nov 13, 2023	BUY	$2.83 - $4.9 $4,709 - $8,153	1,664 Added 2.62%	65,126 $187,000
Q2 2023 Aug 11, 2023	SELL	$1.45 - $6.07 $22,053 - $92,318	-15,209 Reduced 19.33%	63,462 $241,000
Q1 2023 May 12, 2023	BUY	$1.8 - $2.5 $141,607 - $196,677	78,671 New	78,671 $146,000
Q3 2022 Nov 14, 2022	BUY	$2.08 - $5.15 $732 - $1,812	352 Added 0.38%	93,907 $302,000
Q2 2022 Aug 15, 2022	BUY	$1.95 - $5.5 $37,913 - $106,936	19,443 Added 26.23%	93,555 $515,000
Q1 2022 May 16, 2022	BUY	$1.83 - $5.52 $63,462 - $191,428	34,679 Added 87.94%	74,112 $173,000
Q4 2021 Feb 14, 2022	BUY	$5.65 - $14.9 $222,796 - $587,551	39,433 New	39,433 $238,000

75.1K

Ticker GRCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,674,096
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

Stay updated on Invesco Ltd. with notifications on news.